Benzimidazolone P38 Inhibitors
Overview
Authors
Affiliations
The synthesis and in vitro p38 alpha activity of a novel series of benzimidazolone inhibitors is described. The p38 alpha SAR is consistent with a mode of binding wherein the benzimidazolone carbonyl serves as the H-bond acceptor to Met109 of p38 alpha in a manner analogous to the pyridine nitrogen of prototypical pyridylimidazole p38 inhibitors. Potent p38 alpha activity comparable to that of several previously reported p38 inhibitors is observed for this novel chemotype.
Polymorphic structures of 3-phenyl-1-1,3-benzo-diazol-2(3)-one.
Hong D, Lee K Acta Crystallogr E Crystallogr Commun. 2023; 79(Pt 6):534-537.
PMID: 37288468 PMC: 10242737. DOI: 10.1107/S2056989023003961.
McGuire R, Verhoeven S, Vass M, Vriend G, de Esch I, Lusher S J Chem Inf Model. 2017; 57(2):115-121.
PMID: 28125221 PMC: 5342320. DOI: 10.1021/acs.jcim.6b00686.
Armen R, Chen J, Brooks 3rd C J Chem Theory Comput. 2010; 5(10):2909-2923.
PMID: 20160879 PMC: 2772076. DOI: 10.1021/ct900262t.
The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.
Schett G, Zwerina J, Firestein G Ann Rheum Dis. 2007; 67(7):909-16.
PMID: 17827184 PMC: 2754165. DOI: 10.1136/ard.2007.074278.